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n parallel with the development of highly sensitive cytologic screening methods, comprehensive screening programs have allowed early detection and high cure rates in uterine cervical cancer in western countries. However, uterine cervical cancer is still the leading cause of cancer deaths for women in many developing countries. 1, 2 The choice of treatment can be decided by several factors, including stage, histological features and the presence of lymph node metastasis. In general, intraepithelial lesions are treated with superficial ablative techniques and early invasive cancers are removed with surgery or radiotherapy. Although local treatments result in high cure rates in these stages of disease, some patients suffer from treatment complications such as ureterovaginal fistula, urinary tract infection, wound infection or bladder dysfunction. [3] [4] [5] These complications compromise patients' quality of life, despite significant improvement in survival with local treatments. Furthermore, in contrast to the high response rates of localized cervical cancer to treatments, patients with disseminated disease almost always have dismal results. With rarity, metastatic cervical cancer may respond to chemotherapy, but the response duration is usually very short and its adverse effects are sometimes serious. 6, 7 To circumvent these problems with conventional local treatments, a new therapeutic approach is needed. Tumor-specific gene therapy using tissue-specific promoter can be a rational treatment strategy for uterine cervical cancer, since the uterine cervix is readily accessible to an intratumoral approach without invasive techniques. Systemic administration of tumor-specific oncolytic adenovirus may also be an effective and safe treatment option for patients with metastatic disease.
The transmembrane glycoprotein MN/CA9, which was first identified in the highly malignant human cervical carcinoma cell line HeLa, is a member of the carbonic anhydrase family with an ability to catalyze the reversible hydration of carbon dioxide to carbonic acid. [8] [9] [10] MN/ CA9 has been detected in several types of malignancies, but not in normal tissues except for epithelial cells of the gastrointestinal tract. [11] [12] [13] [14] [15] [16] [17] [18] A high level of MN/CA9 protein expression was detected in more than 90% of uterine cervical cancer tissues. 11 These observations suggest that MN/CA9 might be a powerful biomarker for the diagnosis and treatment of uterine cervical cancer.
Conventional cancer gene therapies using adenoviral vectors have usually utilized replication-defective adenoviruses, which have difficulty in infecting all of the cancer cells and only a short duration of cytotoxic gene expression. On the other hand, replication-competent oncolytic adenoviruses can lyse cancer cells by viral replication with subsequent spread to adjacent cancer cells. [19] [20] [21] [22] We constructed a tumor-specific replication-competent adenoviral vector, Ad-MN/CA9-E1a, using MN/CA9 promoter to drive the expression of viral early E1a gene and achieve restricted replication in cells that express the MN/CA9 gene. Here, we describe the construction of tumor-specific oncolytic adenovirus, demonstrating its selective cytotoxicity toward MN/CA9-expressing uterine cervical cancer cells in vitro and in vivo.
Materials and methods

Cells and cell culture
Human cervical cancer cell lines HeLa, C-33 A, and SiHa were purchased from the American Type Culture Collection (ATCC, Manassas, VA). SK-RC-29, a human renal cell carcinoma cell line, was generously provided by Dr Neil H Bander (New York Hospital-Cornell Medical Center, New York, NY).
14,23 911, a transformed human embryonic retinoblast cell line, was obtained from Introgen (Leiden, Netherlands). 24 PER.C6, a transformed human embryonic retinoblast cell line, was obtained from DirectGene (Annapolis, MD). 25 HeLa, C-33 A and SiHa cells were cultured in minimum essential medium (MEM) (Gibco BRL, Grand Island, NY) and SK-RC-29 cells were cultured in RPMI 1640 (Gibco BRL). 911 and PER.C6 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Gibco BRL). All media were supplemented with 100 U/mL penicillin, 100 mg/mL streptomycin and 10% fetal bovine serum (FBS) and maintained at 371C in 5% CO 2 .
Construction and production of the replicationcompetent Ad-MN/CA9-E1a adenovirus All plasmids were constructed according to the standard protocols. 26. Briefly, pMN/CA9E1a was constructed by inserting a 550-bp fragment of MN/CA9 promoter, which was cut out from pMN/CA9PGL3-P by the restriction enzyme EcoRI, into the unique EcoRI site in pDBPAE1II. This pMN/CA9E1a shuttle vector was cotransfected with pJM17 into 911 cells using N-[1-(2, 3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate (DOTAP) (Boehringer Mannheim, Indianapolis, IN) following the manufacturer's protocol 27 to generate the replicationcompetent adenovirus, Ad-MN/CA9-E1a. When 911 cells in the culture medium showed complete cytopathic effects, they were harvested and centrifuged at 1000 g for 10 minutes. The pooled supernatants were aliquoted and stored at À801C as primary viral stock. Viral stocks were propagated in 911 cells and several clones of Ad-MN/CA9-E1a virus were selected by plaque purification.
One of the viral clones was chosen, propagated in PER.C6 cells, harvested 36-40 hours after infection, pelleted, resuspended in phosphate-buffered-saline (PBS) and lysed. Cell debris was removed by centrifugation and viruses in the cell lysate were purified by CsCl gradient centrifugation. Concentrated viruses prepared above were dialyzed, aliquoted and stored at À801C. The viral titer was determined by plaque-forming assay and optical density measurements.
cDNA production and PCR assay for MN/CA9 mRNA
Total RNA was extracted from tested cell lines by disrupting cells in Trizol solution (Gibco BRL). RNA was precipitated by ethanol, dissolved in water treated with diethylpyrocarbonate (DEPC) (Sigma, St Louis, MO). Complementary DNA (cDNA) for total RNA was synthesized by Moloney murine leukemia virus (MMuLV) reverse transcriptase (MBI Fermentas, Hanover, MD) using random hexamer primers. In all, 2 mg of total RNA and 0.2 mg of random hexamer primers were mixed in 20 mL reaction volume, placed at 701C for 5 minutes and then placed on ice. The primer and RNA mixture were combined with 1 mM deoxynucleotide triphosphate, 20 U/mL ribonuclease inhibitor, 50 mM Tris-HCl, 50 mM potassium chloride, 4 mM magnesium chloride and 10 mM DTT. The mixture was added to 20 U/mL MMuLV reverse transcriptase. The reverse transcription reaction was performed at 371C for 1 hour. Samples were stored at À201C.
PCR reaction was performed using MN/CA9 cDNAspecific primers following the methods described by Bartosova et al 18 with minor modifications. Two primers (5 0 -CCG AGC GAC GCA GCC TTT GA-3 0 and 5 0 -TAG TCG ACT AGG CTC CAG TCT CGG CTA CTT-3 0 ) were used to amplify a particular 255-bp fragment within MN/CA9 cDNA. PCR was run for 35 cycles with denaturation at 951C for 20 seconds, annealing at 651C for 30 seconds, and extension at 721C for 40 seconds. PCR products were analyzed on a 1% agarose gel. b-Actin was also included for PCR amplification as an internal control.
Western blotting analysis for adenovirus E1a protein expression
For Ad5 E1a protein detection, 2 Â 10 6 cells plated in 100-mm dishes were infected with 1 MOI of Ad-MN/CA9-E1a for 14 hours. Cells were harvested and lysed in 200 mL of cell lysis buffer (0.1 M Tris-HCl (pH 7.4), 0.5% SDS, 5 mM EDTA, 1 mM phenylmethylsulfonyl fluoride and 1 mM leupeptin) 2 days after viral infection. Lysates were centrifuged at 14,000 rpm for 20 minutes and the supernatants were collected. Total protein was estimated by dye binding assay (Bio-Rad, Hercules, CA). Protein (20 mg) was loaded onto 12% SDS-PAGE gel. The proteins were transferred to polyvinylidene difluoride membrane (PVDF) (Scheleicher & Schuell, Dassel, Germany) and the membrane was probed with antibodies reactive to Ad5 E1a protein (MS-587-P1, NeoMarkers, Fremont, CA). Primary antibodies were detected using a goat anti-mouse secondary antibody conjugated to horseradish peroxidase and visualized by ECL (Amersham, Arlington Heights, IL).
In vitro cytotoxicity assay
HeLa, C-33 A, SiHa or SK-RC-29 cells were seeded onto 24-well plates at a density of 5 Â 10 3 cells/well. After 24 hours, cells were infected with 0.01-100 MOI of Ad-MN/CA9-E1a. Half of the medium was aspirated at days 3 and 5 after viruses were added (day 0) and replaced with fresh medium. The cell numbers per well were assessed at days 0, 1, 3, 5 and 7 by crystal violet assay. The data were presented as the percentage of cell numbers in the virusinfected group relative to the uninfected control group.
In vivo animal studies
Athymic BALB/c nude female mice, 6-week old, weighing 20 g (Japan SLC, Shizuoka, Japan) were inoculated subcutaneously with HeLa cells (2 Â 10 6 cells) in 100 mL of 50% MATRIGEL basement membrane matrix (Becton Dickinson, Bedford, MA). When tumors became palpable (4-5 mm in diameter), animals were randomly assigned to two experimental groups, group 1 (n ¼ 7) for Ad-MN/CA9-E1a and group 2 (n ¼ 7) with PBS. A single dose of 50 mL of Ad-MN/CA9-E1a (2 Â 10 9 pfu) or PBS was injected intratumorally with a microliter syringe fitted with a 28-gauge needle. Tumor volume was measured every 5 days and calculated using the following formula: volume (a rotational ellipsoid) ¼ M 1 Â M 2 2 Â 0.5236 (M 1 , long axis; M 2 , short axis). 28 Tumor volumes were normalized to 100% at day 0. At 30 days after intratumoral injection, the mice were killed and tumors were removed for histological examination.
Results
RT-PCR analysis of MN/CA9 expression
Total RNA was prepared as described in Materials and methods from human cervical (HeLa, C-33 A and SiHa) and renal (SK-RC-29) cancer cells. HeLa cells are known to express MN/CA9 proteins 8, 9 but SK-RC-29 cells do not.
14 As expected, a distinct 255-bp fragment corresponding to the sequence within MN/CA9 cDNA was detected in all three human cervical cancer cells tested, but SK-RC-29 cells did not have MN/CA9 transcripts. HeLa cells showed the most abundant expression of MN/CA9 (Fig 1) .
Western blotting analysis of adenovirus E1a protein expression
Ad5 E1a protein production in HeLa, C-33 A, SiHa or SK-RC-29 cells after infection with Ad-MN/CA9-E1a viruses was determined by Western blotting (Fig 2) . E1a proteins were not detected in any cells prior to infection (data not shown). 
Selective cytotoxicity of Ad-MN/CA9-E1a to MN/CA9-positive cell lines in vitro
To evaluate the selective cytotoxicity of Ad-MN/CA9-E1a virus, we infected each cell line in vitro with a wide range (0.01-100 MOI) of viruses (Fig 3) . The growth of MN/CA9-positive cells was significantly inhibited by small virus particles of Ad-MN/CA9-E1a: HeLa, 0.1 MOI; C-33 A, 0.01 MOI; SiHa, 1 MOI. Unlike MN/CA9-positive cell lines, the growth of the MN/CA9-negative cell line SK-RC-29 was not affected by 0.01-1 MOI. As many as 100 MOI were required to inhibit its growth.
In vivo growth inhibition of HeLa xenograft by Ad-MN/CA9-E1a virus
Human cervical HeLa tumors were induced by subcutaneous injection of HeLa cells into athymic nude mice. After tumor formation, animals were intratumorally injected with Ad-MN/CA9-E1a or PBS as a negative control. The time of virus injection was considered day 0. Tumor volumes were measured at the times indicated in Figure 4 . Ad-MN/CA9-E1a viruses effectively caused growth delay of HeLa xenografts. After 25 days, two of seven mice were visually free of tumor (Fig 5) . Light microscopic observation of tumors in mice injected with Ad-MN/CA9-E1a showed that almost all cancer cells underwent necrosis (Fig 6) . However, tumors in mice injected with PBS showed that cancer cells grew well.
Discussion
Replication-defective recombinant adenoviruses have been widely studied in vivo and in vitro as a vector to deliver cancer therapeutic genes. They can transduce a variety of mammalian cells in a cell replication-independent manner. However, there are several limitations in the use of these vectors for cancer gene therapy. These vectors do not infect all of the cancer cells and permit only a short duration of exogenous gene expression. To circumvent these limitations, replication-competent oncolytic viruses have been developed as an alternative strategy for cancer gene therapy. These can replicate and kill infected cells by viral lysis. Furthermore, the input viral dose is amplified by replication, spreading to adjacent cancer cells after lysis of initially infected cells. Conditional viral gene expression and subsequent replication were achieved using a tissue-specific promoter, resulting in selective replication in the tumor without the damage to neighboring normal cells. [19] [20] [21] [22] There have been several reports comparing viral promoters with the tissue-specific promoters. The minimal enhancer/ promoter from the prostate-specific antigen (PSA) gene has been used to drive E1a expression and create an adenovirus, CN706, that selectively replicates in PSApositive prostate cancer cells. 29 The alpha-fetoprotein (AFP) promoter has also been used to develop the therapeutic adenovirus AvE1a04i, which selectively replicates in AFP-expressing hepatocellular carcinoma cells. 30 MN/CA9 is a transmembrane glycoprotein with apparent molecular weights of 58 and 54 kDa, which was first identified in HeLa cells. [8] [9] [10] Recent reports confirm that MN/CA9 is a potentially important biomarker for uterine cervical carcinoma. MN/CA9 protein was expressed in more than 90% of uterine cervical cancer tissues, but normal cervical tissues did not express this antigen. 11 There was also an association between MN/ CA9 immunostaining of atypical cells in Papanicolaou smears and the presence of significant lesions (adenocarcinoma in situ/carcinoma and cervical intraepithelial neoplasia II or III) in the cervix.
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12 MN/CA9 expression was upregulated in hypoxic cervical cancers and was associated with a poor prognosis in locally advanced uterine cervical cancers. 31 Although the functional significance of MN/CA9 in oncogenesis remains unclear, some evidence supports the role of the MN/CA9 protein in neoplastic progression. MN/CA9 induced a malignant phenotype in murine NIH 3T3 fibroblasts following transfection with MN/CA9 cDNA. 10 Also, MN/CA9 expression correlated with the tumorigenic phenotype of HeLa Â fibroblast somatic cell hybrids; MN/CA9 protein was absent in nontumorigenic hybrid cells (clone CGL1), but it was found in tumorigenic segregants (clones CGL3 and CGL4). Therefore, MN/CA9 may be involved in the control of cell proliferation and transformation. 10, [32] [33] [34] Based on this evidence, MN/CA9 promoter was used to develop an adenovirus, Ad-MN/CA9-E1a, which selectively replicates in MN/CA9-expressing uterine cervical cancer cells. The goal of this study was to create a MN/ CA9 promoter-directed replication-competent adenovirus that could display tumor-specific replication competency and be directly cytotoxic only to uterine cervical cancer cells.
To date, 293 cells generated by transformation of human embryonic kidney cells by sheared Ad5 DNA are the most widely used helper cell line for the production of recombinant adenovirus. 35 However, we chose 911 and PER.C6 cell lines in this experiment because these cell lines possess several favorable characteristics compared to 293 cells. The 911 cell line is an Ad5 E1-transformed human embryonic retinoblast cell with a plasmid containing base pairs 79-5789 of the Ad5 genome. This cell line has comparable quality to 293 cells with respect to transfection efficiency and the frequency of homologous recombination. It also exhibits a shortened plaqueforming time in plaque assay and enhanced viral yields in small-scale production of adenoviral vectors in comparison with 293 cells. 24 Most importantly, since Fallaux et al 24 observed that replication-competent adenoviruses were not generated in the 911-produced replication-defective adenoviral vector batches, we used this cell line for making our replication-competent adenovirus, Ad-MN/CA9-E1a. However, 2 years later, the same group reported that 911 cells could also generate a replication-competent adenovirus in replication-defective adenoviral vector batches and developed a new helper cell line, PER.C6. The PER.C6 cell line, which contains the Ad5 E1a-and E1b-encoding sequences (Ad5 nucleotides 459-3510) under the control of the human phosphoglycerate kinase (PGK) promoter, does not result in the generation of replication-competent adenoviruses. 25 Therefore, we used the PER.C6 cell line for the amplification of Ad-MN/CA9-E1a.
The tissue-specific replication and cytotoxicity of Ad-MN/CA9-E1a adenovirus was assessed in four different cancer cell lines. All three of these uterine cervical cancer cell lines synthesized MN/CA9. HeLa cells, which are known to express MN/CA9 8 , showed the strongest expression of MN/CA9 as assessed by RT-PCR assay. Since one of the renal cell carcinoma cell lines, SK-RC-29, is known to be MN/CA9 negative, 14 we included this cell line as a negative control, confirming the negligible level of MN/CA9 transcripts. Coinciding with the results of RT-PCR assay, Western blotting showed the tissuespecific promoter activity enabling the selective E1a expression in MN/CA9-expressing cells. The in vitro tissue-specific cytotoxicity of Ad-MN/CA9-E1a in MN/ CA9-expressing cells was assessed. Whereas the growth of MN/CA9-positive uterine cervical cancer cell lines was significantly inhibited by a small number of Ad-MN/ CA9-E1a virus particles, the growth of the MN/CA9-negative cell line SK-RC-29 could only be inhibited by a much greater exposure to Ad-MN/CA9-E1a. X-gal staining after infection with Ad-RSV-bgal in SK-RC-29 cells showed that the percentages of b-gal transduced cells were 34% at 2.5 MOI, 45% at 5 MOI, 72% at 10 MOI and 91% at 20 MOI. 36 This suggests that SK-RC-29 cells have a good viral infectivity and the differential cytotoxic effects of Ad-MN/CA9-E1a is due to the difference in MN/CA9 transcriptional activity of the cells, but not that in viral infectivity. Collectively, these results demonstrate that Ad-MN/CA9-E1a has selective cytotoxicity in MN/ CA9-expressing cells with a good therapeutic window. As expected, the intratumoral administration of Ad-MN/ CA9-E1a effectively inhibited the growth of HeLa xenografts in athymic nude mice. After 25 days of viral injection, two of the seven mice were visually free of tumor.
In conclusion, we have established a novel replicationcompetent adenoviral vector using MN/CA9 promoter to drive the replication of adenovirus only in MN/CA9-expressing cancer cells, with selective cytotoxicity and a good therapeutic window. This novel vector system may have potential as a strategy for the treatment of uterine cervical cancer.
